Value of complete metabolic response by 18F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy

European Journal of Cancer

Volumn 43, Issue 9, 2007, Pages 1385-1391

  Kim, Min Kyoung ^a   Ryu, Jin Sook ^a   Kim, Sung Bae ^a   Ahn, Jin Hee ^a   Kim, Soo Young ^a   Park, Seung II ^a   Kim, Yong Hee ^a   Song, Ho Yong ^a   Shin, Ji Hoon ^a   Jung, Hwoon Yong ^a   Lee, Gin Hyug ^a   Choi, Kee Don ^a   Cho, Kyung Ja ^a   Kim, Jong Hoon ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Combined modality therapy; Oesophageal neoplasm; Positron emission tomography; Prognosis

Indexed keywords

CAPECITABINE; CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL;

ACCURACY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOSCOPIC BIOPSY; ENDOSCOPY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METABOLISM; MULTIVARIATE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; SINGLE DRUG DOSE; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS;

EID: 34249899397     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.04.001     Document Type: Article

References (26)

1. Walsh T.N., Noonan N., Hollywood D., Kelly A., Keeling N., and Hennessy T.P. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335 (1996) 462-467
2. Bosset J.F., Gignoux M., Triboulet J.P., et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337 3 (1997) 161-167
3. Urba S.G., Orringer M.B., Turrisi A., Iannettoni M., Forastiere A., and Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19 (2001) 305-313
4. Lee J.L., Park S.I., Kim S.B., et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 15 (2004) 947-954
5. Berger A.C., Farma J., Scott W.J., et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23 (2005) 4330-4337
6. Kim S.B., Park S.I., Kim J.H., et al. A phase II trial of preoperative one cycle of induction chemotherapy[capecitabine(CAP), CDDP] followed by concurrent chemoradiation(CRT) in patients with resectable esophageal cancer. J Clin Oncol 23 (2005) 4063 [abstract]
7. Heath E.I., Burtness B.A., Heitmiller R.F., et al. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 18 (2000) 868-876
8. Ponsner M.C., Forastiere A.A., and Minsky B.D. Cancer of the esophagus. In: Devita T.V., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles & practice of oncology. 7th ed. (2005), Lippincott Williams and Wilkins, Philadelphia (PA) 861-909
9. Stahl M., Stuschke M., Lehmann N., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23 (2005) 2310-2317
10. Jones D.R., Parker Jr. L.A., Detterbeck F.C., and Egan T.M. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 85 (1999) 1026-1032
11. Beseth B.D., Bedford R., Isacoff W.H., Holmes E.C., and Cameron R.B. Endoscopic ultrasound does not accurately assess pathologic stage of esophageal cancer after neoadjuvant chemoradiotherapy. Am Surg 66 (2000) 827-831
12. Rigo P., Paulus P., Kaschten B.J., et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 23 (1996) 1641-1674
13. Swisher S.G., Maish M., Erasmus J.J., et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78 (2004) 1152-1160 [discussion 60]
14. Brucher B.L., Weber W., Bauer M., et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233 (2001) 300-309
15. Flamen P., Van Cutsem E., Lerut A., et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13 (2002) 361-368
16. Levine E.A., Farmer M.R., Clark P., et al. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg 243 (2006) 472-478
17. Song S.Y., Kim J.H., Ryu J.S., et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1053-1059
18. Young H., Baum R., Cremerius U., et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35 (1999) 1773-1782
19. Casson A.G., Rusch V.W., Ginsberg R.J., Zankowicz N., and Finley R.J. Lymph node mapping of esophageal cancer. Ann Thorac Surg 58 (1994) 1569-1570
20. Swisher S.G., Erasmus J., Maish M., et al. 2-Fluoro-2-deoxy-d-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101 (2004) 1776-1785
21. Bar-Shalom R., Guralnik L., Tsalic M., et al. The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging 32 (2005) 918-924
22. Weber W.A., Ott K., Becker K., et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19 (2001) 3058-3065
23. Isenberg G., Chak A., Canto M.I., et al. Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiation. Gastrointest Endosc 48 (1998) 158-163
24. Sarkaria I.S., Rizk N., Bains M., et al. Does endoscopy accurately predict response to chemoradiation in patients undergoing esophagectomy?. J Clin Oncol 24 (2006) 4024 [abstract]
25. Hong D., Lunagomez S., Kim E.E., et al. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer 104 (2005) 1620-1626
26. Chirieac L.R., Swisher S.G., Ajani J.A., et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 103 (2005) 1347-1355